The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

Cancer-associated thrombosis (CAT) carries significant morbidity and mortality. Low-molecular-weight heparin (LMWH) remains the standard of care, with recent systematic studies suggesting the efficacy and safety of rivaroxaban in the treatment of CAT. Uncertainty, however, remains regarding rivaroxa...

Full description

Bibliographic Details
Main Authors: Mouhand F. H. Mohamed MD, MSc, Mohamad Nabil ElShafei PharmD, Mohamed Badie Ahmed, Lina O. Abdalla MBBS, Israa Ahmed MBBS, Abdel-Naser Elzouki MD, PhD, Mohammed ibn-mas’ud Danjuma MBBS, MSc, PhD
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029620940046

Internet

https://doi.org/10.1177/1076029620940046

Similar Items